Turkish Brothers With Virus But No Symptoms Confirm Genomed's Approach To Bird Flu

Main Category: Bird Flu / Avian Flu
Also Included In: Flu / Cold / SARS
Article Date: 12 Jan 2006 - 3:00 PDT

email to a friend   printer friendly   opinions  

GenoMed (OTC Pink Sheets GMED), a Next Generation Disease Management company whose business is public health, announced today that its approach to avian influenza was confirmed today by the finding of two brothers with evidence of avian influenza infection but no symptoms.

The two brothers are being watched in Kecioren Hospital, Turkey, and were the subject of several news reports, for example, CLICK HERE - reuters .

Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, "This finding confirms our impression that what kills members of the general population is not the virus, but their reaction to the virus. Our treatment approach is designed to convert everybody in the general population into asymptomatic viral shedders like these two boys."

About GenoMed

GenoMed's broad-spectrum anti-viral approach is specifically mentioned in BioShield II, (see Section 2151 of Senate bill S. 975). GenoMed uses already existing, safe medication present in every drug store and hospital in the world. Anyone interested in participating in GenoMed's clinical trial for avian influenza or regular influenza can download the trial documents from www.genomed.com.

Safe Harbor Statement
This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) finances and treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

David W. Moskowitz MD
CEO, GenoMed
dwmoskowitz@genomed.com
http://www.genomed.com

• Additional
• References
• Citations